Sign In
Buy ALDX
$1.86
+0.220 (+13.41%)
At Close: Jun 03, 2026
Aldeyra Therapeutics eye treatment meets late-stage study main goal
07:18am, Thursday, 15'th Jun 2023
Aldeyra Therapeutics said on Thursday its experimental drug to treat an inflammatory eye disease met the main goal of reducing itching in a late-stage study.
Aldeyra Therapeutics' stock jumps 11% premarket after announcing positive trial of treatment for allergic conjunctivitis
07:18am, Thursday, 15'th Jun 2023
Aldeyra Therapeutics Inc.'s stock ALDX, +0.63% jumped 11% premarket Thursday, after the biotech announced positive results from a late-stage trial of a treatment for allergic conjunctivitis. The Lexin
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced it will host a webcast and conference call on Thursday, June 15, 2023, at 8:00 a.m. (ET) to provi
Aldeyra Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference
07:00am, Friday, 02'nd Jun 2023
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company developing innovative therapies for the treatment of immune-mediated dise
Buy Aldeyra Therapeutics For Consecutive Runups
01:23am, Saturday, 06'th May 2023
They headlined 3 top-line results coming in Q2 2023. An all-important PDUFA Date is on tap in June.
Aldeyra Therapeutics, Inc. (ALDX) Q4 2022 Earnings Call Transcript
10:45am, Thursday, 09'th Mar 2023
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX ) Q4 2022 Earnings Conference Call March 9, 2023 8:00 AM ET Company Participants Bruce Greenberg - Interim Chief Financial Officer Todd Brady - President and Ch
Aldeyra Therapeutics: NDA Submission For Large Multi-Billion Dollar Market
07:17am, Sunday, 11'th Dec 2022
New Drug Application of Reproxalap for the treatment of patients with dry eye disease submitted on November 29, 2022; Potential FDA approval possible in late 2023. Results from the phase 3 INVIGORATE-
Aldeyra Therapeutics, Inc. (ALDX) Q3 2022 Earnings Call Transcript
01:40pm, Thursday, 10'th Nov 2022
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX ) Q3 2022 Earnings Conference Call November 10, 2022 8:00 AM ET Company Participants Bruce Greenberg - Interim Chief Financial Officer Todd Brady - President an
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced it will host a webcast and conference call on Thursday, October 6, 2022, at 8:00 a.m. (ET) to rep
Aldeyra Therapeutics: Dry Eye Is Just The Beginning For Novel MOA
08:28am, Monday, 19'th Sep 2022
Shares have bucked weakness in the biotech sector and risen 60% year to date. Dry eye disease is a lucrative indication for reproxalap (albeit with generic competition) and differentiation is apparent
Aldeyra Therapeutics, Inc. (ALDX) Now Trades Above Golden Cross: Time to Buy?
01:55pm, Monday, 15'th Aug 2022 Zacks Investment Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
$2 Million Bet On This Industrial Stock? 4 Stocks Insiders Are Buying
12:37pm, Monday, 08'th Aug 2022 Benzinga
Although US stocks closed mixed on Friday, there were a few notable insider trades.
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock
Aldeyra Therapeutics (ALDX) Q2 2022 Earnings Call Transcript
07:00am, Sunday, 07'th Aug 2022 The Motley Fool
ALDX earnings call for the period ending June 30, 2022.
Aldeyra Therapeutics, Inc. (ALDX) CEO Todd Brady on Q2 2022 Results - Earnings Call Transcript
02:01pm, Friday, 05'th Aug 2022
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX ) Q2 2022 Earnings Conference Call August 5, 2022 8:00 AM ET Company Participants Bruce Greenberg - Interim Chief Financial Officer Todd Brady - President & Chi
Aldeyra Therapeutics: Poised For Dry Eye Disease Therapy Monetization
02:25am, Thursday, 04'th Aug 2022
Reproxalap seems poised for FDA approval for dry eye disease. Therapy has clear practical advantages over Restasis and Xiidra.
